Comparing a new PSMA scan to MRI for prostate cancer detection
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a new imaging agent (flotufolastat F 18 PET CT) can find prostate cancer better than MRI. If you have a suspicious spot on an MRI, this study may help doctors see if the new scan is more accurate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 90 years old.
- You have had an MRI in the past year showing a suspicious spot (PI-RADS 3-5).
- You have not been treated for prostate cancer before.
- You can safely stop taking blood thinners for 7 days before a biopsy.
- You are not taking any other experimental drugs within 6 weeks of starting.
- You do not have severe claustrophobia or other reasons you cannot lie still for imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging scan that combines a special PET tracer with MRI to help guide a prostate biopsy. The goal is to see if this scan can more accurately find cancer and reduce the need for extra biopsies.
This trial tests a new PET scan (a type of imaging) called Flotufolastat to see if it can better monitor prostate cancer after you receive focal therapy—a treatment that targets only the cancer area rather than the whole prostate. The goal is to help doctors know if the treatment worked and catch any remaining cancer early.
This trial tests whether a special PET scan (called POSLUMA) can help find prostate cancer earlier in men who have an MRI showing a suspicious spot (PIRADS 2 or 3) but haven't yet had a biopsy. If you are scheduled for a biopsy, this scan may give your doctor extra information before the procedure.
This trial compares two types of PET/CT scans (using different radioactive tracers) to see which is better at finding prostate cancer, tracking its return, or spotting spread. It's for people with prostate cancer or those being checked for recurrence after treatment.
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
This trial tests if a special PET scan (PSMA-PET) plus MRI is better than MRI alone at finding the full extent of high-risk prostate cancer before surgery. It aims to improve surgical planning by checking scan results against the removed prostate tissue.
Hear when a new Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.